talactoferrin alfa has been researched along with Sepsis in 4 studies
talactoferrin alfa: recombinant human lactoferrin, an oral drug for treatment of refractory solid tumors; in Phase I trial 5/2006
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Administration of oral talactoferrin was not associated with reduced 28-day mortality in patients with severe sepsis and may even be harmful." | 9.20 | Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial. ( Dellinger, RP; Guntupalli, K; Levy, MM; Malik, R; Marshall, JC; Simonson, SG; Singer, M; Vincent, JL, 2015) |
| "Enteral administration of talactoferrin reduced 28-day all-cause mortality in patients with severe sepsis." | 9.17 | A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. ( Bandi, V; Dean, N; Dellinger, RP; Guntupalli, K; Ismail, PM; Levy, M; Lodato, RF; Malik, R; Margolis, B; Morris, PE; Reese, A; Rivers, E; Schaumberg, JP, 2013) |
| "Administration of oral talactoferrin was not associated with reduced 28-day mortality in patients with severe sepsis and may even be harmful." | 5.20 | Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial. ( Dellinger, RP; Guntupalli, K; Levy, MM; Malik, R; Marshall, JC; Simonson, SG; Singer, M; Vincent, JL, 2015) |
| "Enteral administration of talactoferrin reduced 28-day all-cause mortality in patients with severe sepsis." | 5.17 | A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. ( Bandi, V; Dean, N; Dellinger, RP; Guntupalli, K; Ismail, PM; Levy, M; Lodato, RF; Malik, R; Margolis, B; Morris, PE; Reese, A; Rivers, E; Schaumberg, JP, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guntupalli, K | 2 |
| Dean, N | 1 |
| Morris, PE | 1 |
| Bandi, V | 1 |
| Margolis, B | 1 |
| Rivers, E | 1 |
| Levy, M | 1 |
| Lodato, RF | 1 |
| Ismail, PM | 1 |
| Reese, A | 1 |
| Schaumberg, JP | 1 |
| Malik, R | 2 |
| Dellinger, RP | 2 |
| McCulloh, R | 1 |
| Opal, SM | 1 |
| Vincent, JL | 1 |
| Marshall, JC | 1 |
| Simonson, SG | 1 |
| Levy, MM | 1 |
| Singer, M | 1 |
| Sherman, MP | 1 |
| Adamkin, DH | 1 |
| Niklas, V | 1 |
| Radmacher, P | 1 |
| Sherman, J | 1 |
| Wertheimer, F | 1 |
| Petrak, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis[NCT00630656] | Phase 2 | 190 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis[NCT01273779] | Phase 2/Phase 3 | 1,280 participants (Anticipated) | Interventional | 2011-06-30 | Suspended (stopped due to Data Safety Monitoring Board recommendation) | ||
| Phase 1/2 Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants[NCT00854633] | Phase 1/Phase 2 | 120 participants (Anticipated) | Interventional | 2009-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for talactoferrin alfa and Sepsis
| Article | Year |
|---|---|
A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis.
Topics: Adult; Aged; APACHE; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hospital Mortali | 2013 |
Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; APACHE; Double-Blind Method; Female; Humans; | 2015 |
Randomized Controlled Trial of Talactoferrin Oral Solution in Preterm Infants.
Topics: Administration, Oral; Bacteremia; Cross Infection; Double-Blind Method; Enterocolitis, Necrotizing; | 2016 |
1 other study available for talactoferrin alfa and Sepsis
| Article | Year |
|---|---|
Human recombinant lactoferrin for sepsis: too good to be true?.
Topics: Female; Humans; Lactoferrin; Male; Sepsis | 2013 |